Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.
Also called NCT07060456
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 300 participants
- Registry
-
NCT07060456
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07060456. Randomized; triple masking; primary purpose treatment. Start 2025-07-25 (actual); primary completion 2027-02 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- HRS9531
- Intervention (Drug)
- HRS9531
- Intervention (Drug)
- Placebo
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07060456- Content hash
0433d435ffb6fac48c764e0092a6a441b325d2d4a9c5657ad98bc1d155a7896e